Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026)

Kiniksa Pharmaceuticals International's Research & Development history runs 10 years deep, the most recent figure standing at $27.5 million for Q1 2026.

• Quarterly Research & Development rose 42.17% year-over-year to $27.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.0 million (changed 0.37% YoY) and the FY2025 annual result came in at $96.9 million, down 13.23% from the prior year.
• Research & Development was $27.5 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $34.6 million in the prior quarter.
• Across five years, Research & Development topped out at $35.2 million in Q4 2024 and bottomed at $13.8 million in Q2 2022.
• A 5-year average of $22.2 million and a median of $20.8 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development plunged 47.54% — and 2024, when it jumped 75.62%.
• Kiniksa Pharmaceuticals International's Research & Development stood at $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then jumped by 75.62% to $35.2 million in 2024, then decreased by 1.72% to $34.6 million in 2025, then decreased by 20.61% to $27.5 million in 2026.
• Business Quant data shows KNSA's Research & Development at $27.5 million in Q1 2026, $34.6 million in Q4 2025, and $24.2 million in Q3 2025.